Key Takeaways
- • First Irish-domiciled cannabis fund launches: The Óskare Fund, a joint venture between Irish firm Crossroads Capital Management and French cannabis investment specialist Óskare Capital, has become the first cannabis investment fund to be domiciled in Ireland, receiving Central Bank approval in the preceding month (May 2020).
- • €30 million initial fundraising target: The Irish-French venture is targeting €50 million in total capital, with €30 million planned for the initial fundraising phase focused on private cannabis investments across Europe.
- • Regulatory milestone in emerging market: The Central Bank's approval signals institutional acceptance of cannabis as an alternative investment asset class in Ireland, despite cannabis remaining illegal for recreational use and requiring case-by-case ministerial approval for medical applications in the jurisdiction.
- • Professional infrastructure in place: The fund is backed by established legal counsel from Eversheds Sutherland, indicating institutional-grade governance and compliance frameworks appropriate for institutional and family office capital.
Summary
Ireland has entered the cannabis investment space with the launch of the Óskare Fund, marking the first cannabis-focused investment fund to be domiciled in the country. The fund is a partnership between Crossroads Capital Management, an Irish investment firm, and Óskare Capital, a France-based cannabis investment specialist. The initiative received approval from Ireland's Central Bank in May 2020, establishing a regulated framework for cannabis-focused alternative investments in the jurisdiction.
The Óskare Fund is targeting €50 million in total capital deployment, with the initial fundraising phase focused on securing €30 million to deploy across private cannabis investments in Europe. This capital raise represents a significant institutional commitment to the cannabis sector at a time when the industry remains nascent in many European markets. The fund's strategy appears positioned to capitalize on the growing divergence between regulatory frameworks across Europe, where certain jurisdictions have moved toward medical cannabis legalization while others maintain full prohibition.
The fund's legal and advisory infrastructure reflects institutional-grade standards, with Eversheds Sutherland providing legal counsel. This professional positioning is designed to appeal to sophisticated investors including family offices, hedge funds, and institutional allocators seeking exposure to the cannabis sector through a regulated, compliant vehicle. The Central Bank's approval demonstrates regulatory acceptance of cannabis as a legitimate alternative investment asset class in Ireland, despite the country's continued prohibition of recreational cannabis and restrictive medical cannabis approvals requiring individual ministerial authorization.
The launch occurs against a backdrop of evolving European cannabis policy, with jurisdictions including Germany, Portugal, and Luxembourg advancing medical and therapeutic cannabis frameworks. The Óskare Fund's European investment focus suggests management confidence in further regulatory liberalization across the continent, positioning early institutional capital to benefit from policy shifts and market maturation in cannabis-derived products and cultivation.
The Óskare Fund is targeting €50 million in total capital deployment, with the initial fundraising phase focused on securing €30 million to deploy across private cannabis investments in Europe. This capital raise represents a significant institutional commitment to the cannabis sector at a time when the industry remains nascent in many European markets. The fund's strategy appears positioned to capitalize on the growing divergence between regulatory frameworks across Europe, where certain jurisdictions have moved toward medical cannabis legalization while others maintain full prohibition.
The fund's legal and advisory infrastructure reflects institutional-grade standards, with Eversheds Sutherland providing legal counsel. This professional positioning is designed to appeal to sophisticated investors including family offices, hedge funds, and institutional allocators seeking exposure to the cannabis sector through a regulated, compliant vehicle. The Central Bank's approval demonstrates regulatory acceptance of cannabis as a legitimate alternative investment asset class in Ireland, despite the country's continued prohibition of recreational cannabis and restrictive medical cannabis approvals requiring individual ministerial authorization.
The launch occurs against a backdrop of evolving European cannabis policy, with jurisdictions including Germany, Portugal, and Luxembourg advancing medical and therapeutic cannabis frameworks. The Óskare Fund's European investment focus suggests management confidence in further regulatory liberalization across the continent, positioning early institutional capital to benefit from policy shifts and market maturation in cannabis-derived products and cultivation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.